Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

First-Line Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: docetaxel
Drug: gemcitabine hydrochloride
Drug: vinorelbine tartrate

First Posted Date: 2008-08-18

Last Posted Date: 2011-02-24

Lead Sponsor: Yonsei University

Target Recruit Count: 117

Registration Number: NCT00736814

Locations: 🇰🇷
Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Ramucirumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-08-15

Last Posted Date: 2014-12-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 41

Registration Number: NCT00735696

Locations: 🇬🇧
ImClone Investigational Site, London, United Kingdom

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Genetic: protein expression analysis
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis

First Posted Date: 2008-08-07

Last Posted Date: 2018-04-02

Lead Sponsor: Greg Otterson

Target Recruit Count: 63

Registration Number: NCT00729612

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: carboplatin
Drug: hydroxychloroquine
Drug: paclitaxel

First Posted Date: 2008-08-06

Last Posted Date: 2017-05-23

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 8

Registration Number: NCT00728845

Locations: 🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Abraxane
Drug: Carboplatin
Drug: Avastin

First Posted Date: 2008-07-28

Last Posted Date: 2021-04-29

Lead Sponsor: William Sikov MD

Target Recruit Count: 60

Registration Number: NCT00723125

Locations: 🇺🇸
Yale Smilow Cancer Center, New Haven, Connecticut, United States
🇺🇸
The Miriam Hospital, Providence, Rhode Island, United States
🇺🇸
Women and Infants, Providence, Rhode Island, United States

and more 2 locations

Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: ABT-869
Drug: Placebo for ABT-869
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-07-16

Last Posted Date: 2013-04-29

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 145

Registration Number: NCT00716534

Locations: 🇺🇸
Site Reference ID/Investigator# 13101, Philadelphia, Pennsylvania, United States
🇺🇸
Site Reference ID/Investigator# 24122, Philadelphia, Pennsylvania, United States
🇧🇷
Site Reference ID/Investigator# 22684, Santo Andre, Brazil

and more 34 locations

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Bortezomib
Drug: Carboplatin
Drug: Docetaxel

First Posted Date: 2008-07-14

Last Posted Date: 2019-06-24

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 6

Registration Number: NCT00714246

Locations: 🇺🇸
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Docetaxel, Cisplatin and Fluorouracil in Treating Patients with Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Sinonasal Undifferentiated Carcinoma
Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC V8

Interventions: Drug: Carboplatin
Other: Chemoradiotherapy
Drug: Cisplatin
Procedure: Definitive Surgical Resection
Drug: Docetaxel
Drug: Fluorouracil
Procedure: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2008-06-30

Last Posted Date: 2024-12-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00707473

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Chemoradiation Treatment for Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Cetuximab
Drug: Carboplatin
Radiation: Radiotherapy

First Posted Date: 2008-06-25

Last Posted Date: 2017-07-12

Lead Sponsor: Trans Tasman Radiation Oncology Group

Target Recruit Count: 60

Registration Number: NCT00704639

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-fluorouracil (5-FU)

First Posted Date: 2008-06-16

Last Posted Date: 2014-11-21

Lead Sponsor: Ministry of Health, Malaysia

Target Recruit Count: 18

Registration Number: NCT00697905

Locations: 🇲🇾
Ipoh Specialist Centre, Ipoh, Malaysia
🇲🇾
Johor Specialist Centre, Johor Bahru, Malaysia
🇲🇾
Tung Shin Hospital, Kuala Lumpur, Malaysia

and more 8 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy